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Abstract
Background: Survival analysis using time-updated CD4+ counts during antiretroviral therapy is frequently employed to
determine risk of clinical events. The time-point when the CD4+ count is assumed to change potentially biases effect
estimates but methods used to estimate this are infrequently reported.
Methods: This study examined the effect of three different estimation methods: assuming i) a constant CD4+ count from
date of measurement until the date of next measurement, ii) a constant CD4+ count from the midpoint of the preceding
interval until the midpoint of the subsequent interval and iii) a linear interpolation between consecutive CD4+
measurements to provide additional midpoint measurements. Person-time, tuberculosis rates and hazard ratios by CD4+
stratum were compared using all available CD4+ counts (measurement frequency 1–3 months) and 6 monthly
measurements from a clinical cohort. Simulated data were used to compare the extent of bias introduced by these
methods.
Results: The midpoint method gave the closest fit to person-time spent with low CD4+ counts and for hazard ratios for
outcomes both in the clinical dataset and the simulated data.
Conclusion: The midpoint method presents a simple option to reduce bias in time-updated CD4+ analysis, particularly at
low CD4 cell counts and rapidly increasing counts after ART initiation.
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Introduction
Observational prospective cohort data of patients on antiretro-
viral therapy (ART) are often used to estimate the relationship
between time-varying CD4+ counts and incident clinical events
such as tuberculosis (TB), death, opportunistic infections and
malignancies. These studies aim to investigate the effect of actual
CD4+ count on morbidity and mortality by using time-varying
measures. While within-subject CD4+ count variability [1,2,3] will
inevitably introduce measurement error, measurement frequency
and the choice of when to split time attributed to a certain CD4+
count value might also introduce bias. Measurement frequencies
are either determined by the study protocol which specifies time
intervals at which individuals are followed (interval cohort) or by
prevailing guidelines within the health care service (clinical cohort)
[4]. In the latter the frequency of visits and laboratory measure-
ments may also be influenced by the severity of illness, access to
and utilization of health care which might increase the bias.
Differences in measurement frequency between two exposure
groups have been shown to introduce bias when time to a specific
biomarker level is used as a surrogate outcome [5]. The time-point
when the CD4+ count is assumed to change might bias effect
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CD4+ counts are rapidly changing. A literature review of studies
published between January 2006 and August 2010 investigating
the effect of time-updated CD4+ counts on mortality and
morbidity found that the majority (11/21) of studies did not did
not specify the method used to estimate the time-point of change
(table 1). Of remaining studies, eight assumed that the CD4+
count remains constant until the date of the next measurement
and two studies used linear interpolation between two consecutive
CD4+ count measurements to provide a midpoint measurement
and time-point.
We aimed to assess how different methods of dealing with time
points influence effect estimates and rates using data from a
clinical ART cohort with frequent measurements. We used the
two methods most frequently used in the literature and
investigated the effect of a third method assuming that the
CD4+ count remains constant from the midpoint of the preceding
interval until the midpoint of the subsequent interval.
The clinical ART cohort used for this study was based in Cape
Town, South Africa and CD4+ counts were measured monthly for
the first 3 months and 3 monthly thereafter. We also investigated
the direction of bias using a simulated dataset.
Methods
Data collection
Data collected in a peri-urban township in the greater area of
Cape Town as part of the CIPRA-SA trial were used for this
analysis [6]. The trial randomized patients to nurse or doctor-
monitored HIV care and showed equivalence of the two
monitoring strategies for treatment failure over 2 years. A total
of 363 HIV-positive ART-naı ¨ve patients with a CD4 cell count of
Table 1. Studies conducting analysis using time-updated CD4+.
Author Journal Outcome CD4+ count Description of how time-updated CD4+ counts were determined.
Dunn[26] JID AIDS or death exposure Follow-up time from the time that each measurement was obtained was censored at the
date of the next measurement.
Guiguet[27] Open AIDS J AIDS or death exposure CD4+ counts were modeled using linear interpolation between two measurements.
Lawn[25] AIDS Death exposure Person time was divided into intervals each of which was defined by the CD4+ count
measurement at the start of the interval.
Lawn[11] AIDS Tuberculosis exposure Person-time was subdivided into 4-month intervals for analysis. Each interval was defined
by theCD4 cell count measurement at the start of the interval.
Reekie[13] Cancer non-AIDS-defining
malignancies
exposure
d’Arminio
Monforte[28]
AIDS death from
malignancies
exposure Each person’s follow-up was divided into a series of consecutive 1-months periods, and
the individual’s status (most recent CD4+ count) was determined.
Lodi[14] J Natl
Cancer Inst
Kaposi sarcoma exposure
Engels[29] JAIDS Non-Hodgkin
Lymphoma
exposure We considered the most recent laboratory result ‘‘current’’ until the next measurement.
Crum-
Cianflone[16]
Arch Intern
Med
Cutaneous
malignancy
exposure
Guiguet[30] Lancet
Oncology
Malignancies exposure Follow-up was divided into consecutive 1-month periods, and time-varying covariables
were updated at the beginning of every month. The CD4+ count was linearly interpolated
unless ART was started between 2 measurements.
Podlekareva[31] Sand J Infec Dis Fungal infections exposure
Prosperi[17] CID Malignancies exposure
Seyler[18] AIDS Res Human
Retroviruses
Severe
morbidity
exposure
Sogaard[32] PLoS one Death from
pneumonia
confounder CD4+ counts were estimated between measurements by carrying forward the value from
the most recent measurement
Walker[19] Lancet Effect of Co-
trimoxazole
confounder
Crum-
Cianflone[15]
AIDS Malignancies exposure
Phillips[33] AIDS Death exposure Person time was counted from the time of each qualifying CD4+ count until the next
CD4+ count.
Beaudrap[20] BMC
Infect Dis
AIDS defining
illness
exposure
Mocroft[21] AIDS Clinical disease
progression
exposure
Bohlius[22] Antivir
Ther
Non-Hodgkin
Lymphoma
exposure
Bruyand[34] CID Malignancies exposure We assumed that the value of the measurement reported at a given follow-up visit
remained stable until the next follow-up visit
doi:10.1371/journal.pone.0027763.t001
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were enrolled in the trial in Cape Town. All patients received a
standard ART regimen and were managed according to the South
African National Guidelines [7].
CD4+ counts were measured at weeks 24, 0, 4, 8, 12 (relative to
the start of ART) and then every 12 weeks. Incident TB was used
as the outcome of interest. Start and end of TB treatment were
determined by merging the ART register with the electronic TB
register on first name, surname, medical record number, date of
birth, truncation of names and switching of first name and
surname. This method was validated by clinical folder review in a
similar dataset of 585 patients from a different study and revealed
96.1% sensitivity and 97.4% specificity. All identifiers were
removed from the data after merging.
Individuals who did not live in the study community and
individuals who were on TB treatment at ART initiation and died
or were lost to follow-up before they completed treatment were
excluded from the analysis.
The exposure was time-updated CD4+count and the outcome
was incident TB defined as starting TB treatment. Person-time
accrued from ART initiation to the date of TB disease, death,
becoming lost to follow-up or the 31
st December 2008 was
calculated. Individuals who were on TB treatment at time of ART
initiation were only included in the analysis after they had
completed TB treatment. Individuals who developed incident TB
were re-included in the analysis after completing TB treatment.
Individuals only contributed time while they were on ART and
person-time while defaulting care was excluded from the analysis,
as neither the exposure (CD4+ count) not the outcome (TB) was
known for these periods.
Time-updated CD4 count
The data were analyzed in three different ways: the first analysis
assumed that the CD4+ count changed at the date when the blood
sample for CD4+ count measurement was drawn (date of
measurement analysis) (figure 1A); the second assumed a change
of CD4+count at the midpoint between two measurements
(midpoint analysis) (figure 1B); and the third calculated an
additional CD4+ count using a linear interpolation between two
consecutive CD4+ measurements and used the date when the
blood samples were drawn and the midpoint between the two
dates as the time point of change of CD4+ count (linear
interpolation analysis) (figure 1C).
Newly generated datasets
A dataset including baseline CD4+ counts and 6-monthly CD4+
counts only was generated. From this dataset 15% of the follow-up
CD4+ counts were randomly selected and removed to simulate the
realityofmissing data in clinical cohorts. A totalof 100 datasetswith
15% randomly missing follow-up CD4+ counts were generated.
Gold standard dataset
The effect estimates and person-time using the newly generated
dataset with 6-monthly CD4+ counts and different methods to
estimate time-point of change were compared with results
obtained when analysing the dataset using all available CD4+
counts (gold standard dataset). The gold standard dataset included
CD4+ counts measured on a monthly bases from 0–3 months on
ART, followed by 3-monthly CD4+ counts until death, loss-to-
follow up, transfer out or censoring. Table 2 shows the difference
in median CD4+ counts over time in the gold standard dataset and
the 6-monthly dataset using different methods to estimate the
time-point of CD4+ change.
Statistical analysis
All analyses were carried out using Stata version 11.0 (Stata
Corp. LP, College Station, TX, United States of America). The
association between time-updated CD4+ count and TB was
explored describing the rate of incident TB and using crude
Kaplan-Meier curves. Cox proportional hazard regression was
used to model the relationship between time-updated CD4+ count
and TB. Hazard proportionality was assessed by analysis of scaled
Schoenfeld residuals.
Events, person-time, rates, hazard ratios and standard errors
were determined for the 100 datasets with 15% randomly missing
follow-up data. The overall estimates were calculated according to
the combination rules described by Rubin [8].
Simulated CD4+ dataset
Simulated CD4+ count data by time since treatment initiation and
baseline CD4+ strata, CD4i(t), were generated by fitting
CD4i(t)~CD4i(t0)zCD4i(tm)(1{e{rit) to empirical data from
Figure 1. Illustration of the three different methods of modeling CD4+ count. In the patient shown, we actually observed 11 CD4+ cell
counts over the two years (grey line). We have illustrated what would have been modeled if only the results at 6 month intervals (black diamonds)
had been available. Dotted and dashed lines (black) are the CD4+ counts assumed by the three different methods: data of measurement (A),
midpoint (B) and linear interpolation (C).
doi:10.1371/journal.pone.0027763.g001
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treatment initiation, twas time since treatment initiation, CD4i(t0)
was the average CD4+ level in strata i at treatment initiation,
CD4i(tm) was a parameter determining the increase in CD4+ count
in strata i after 5 years of treatment, and ri was a parameter
determining the rate of CD4+ count increase in strata i.E a c hC D 4 +
stratumi was simulated separatelyand the results werealsocombined
to generate a ‘mixed’ cohort of 25%, 17%, 18%, 15%, 25% of
patients with baseline CD4+ of 25–50 cells/uL, 51–100 cells/uL,
101–150 cells/uL, 151–200 cells/uL and 201–300 cells/uL respec-
tively, to represent a mix of patients seen in a typical clinic. A clinical
South African ART cohort was used to determine the proportions of
patients in different CD4+ count strata for the mixed cohort [10].
The areas under the CD4+ curve (AUC) were calculated using
date of measurement, midpoint or linear interpolation methods
with either 6 monthly or 3 monthly measurements. The AUC
measures CD4 exposure. It is derived from the actual CD4+
values and the time spent with these values. Rates were calculated
assuming constant rates within CD4+ count strata using TB rate
estimates from published literature [11,12].
Ethical approval
All patientsintheCIPRA-SAtrial signedinformed consentforms.
The trial was approved by the University of Cape Town Ethics
Committee and Partners Human Subjects Institutional Review
Board. The London School of Hygiene and Tropical Medicine
Ethics Committee and the University of Cape Town Ethics
Committee and Partners Human Subjects Institutional Review
Board gave approval for the analysis of the anonymised data.
Results
TB incidence and hazard ratios by time-updated CD4+
count using clinical cohort data
Overall TB incidence was 4.9/100 person–years (PY) (95%
confidence interval (CI) 3.6–6.8). TB incidence rates were 14.7 in
the lowest CD4+ count stratum (#200 cells/uL), 3.1 in the middle
CD4+ count stratum (201–350 cells/uL) and 2.9 in the highest
CD4+ count stratum (.350 cells/uL) when using all available
CD4+ counts and performing a date of measurement analysis
(table 3). The midpoint analysis revealed TB incidence rates of
16.0, 3.1 and 2.8 for the three different CD4+ count categories.
The total person-time spent at low CD4+ counts was less in the
midpoint analysis compared to the date of measurement analysis.
TB incidence rates and hazard ratios (HRs) were different when
using a dataset with 6 monthly CD4+ counts as compared to
analysis using all available CD4+ counts (table 3). With all three
estimation methods, compared to the results with more frequent
measures, rates were underestimated at low and high CD4+
counts, and overestimated at moderate CD4+ counts, with most
marked overestimation in the midpoint analysis.
Analyses using a dataset with 6 monthly CD4+ counts and 15%
randomly missing follow-up CD4+ counts revealed more extreme
variations in rates, but with the same pattern of underestimation at
low and high counts, and overestimation at moderate counts
(table 3). The differences in rates and HRs compared to the
analysis using all available data were most pronounced using the
date of measurement analysis, and least pronounced using the
midpoint analysis.
Area under the CD4+ curve using simulated data
The midpoint analysis estimated the AUC most accurately for
cohorts with low (25–50 cell/uL), high (151–200 cells/uL) and
mixed baseline CD4+ counts (table 4). The date of measurement
analysis underestimated the AUC for all cohorts and time-points.
The relative difference was most pronounced in cohorts with low
baseline CD4 counts and short follow-up (1 year). The date of
measurement analysis was less accurate with 3 monthly measure-
ments than the midpoint analysis with 6 monthly measurements.
TB rates using simulated data
Both the date of measurement and midpoint analysis underes-
timated TB rates for low CD4+ count strata (,200 cell/uL). Rates
were less accurately estimated using the date of measurement
analysis compared to the midpoint analysis (table 5). Rates for
some CD4 count+ strata could not be determined as no time was
spent in those strata. For example a cohort with a baseline CD4
count of 151–200 did not accumulate any person-time in the
CD4+ count strata #50 and 51–100. In addition cohorts with
baseline CD4+ counts of 25–50 and 51–100 did not improve their
CD4+ count beyond 400 over the 5 year period and thus did not
accumulate any time in higher CD4+ count strata.
Discussion
This study shows that the time-point when a CD4+ count is
assumed to change influences incidence rates of clinical events
during ART and effect estimates in time-updated CD4+ count
analysis. The analysis using modeled CD4+ count data showed
that the midpoint method gives a better approximation of person-
time spent at low CD4+ counts compared to the date of
measurement method. The choice of time-point when a CD4+
Table 2. Median CD4 counts and interquartile ranges at baseline, 1, 2, 3, 6, 9 and 12 months follow-up using different methods to
estimate the time-point of change of CD4+ count.
Months All available CD4+ counts 6 monthly CD4+ counts only
Date of measurement Midpoint Linear interpolation
0 191.5 (109–256) 191.5 (109–256) 191.5 (109–256) 191.5 (109–256)
1 265 (185.5–365.5) 191.5 (109–256) 191.5 (109–256) 191.5 (109–256)
2 296 (198–381) 191.5 (109–256) 191.5 (109–256) 191.5 (109–256)
3 291.5 (198–380) 191.5 (109–256) 307 (213.5–432.5) 248 (158–324)
6 307 (213.5–432.5) 307 (213.5–432.5) 307 (213.5–432.5) 307 (213.5–432.5)
9 313.5 (213.5–432.5) 307 (213.5–432.5) 333 (236–4447) 318 (222–404)
12 333 (236–4447) 333 (236–4447) 333 (236–4447) 333 (236–4447)
doi:10.1371/journal.pone.0027763.t002
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low baseline CD4+ counts and during the first year after ART
initiation. While the absolute difference in effect estimates was
small when analyzing data with frequent measurements, the
choice of time-point was important in data with less frequent and
missing measurements. Thus the frequency of measurement and
the method used to determine the time-point of change in CD4+
count need to be taken into account when comparing effect
estimates from different studies. However, most studies per-
forming survival or Cox regression analysis with time-updated
CD4+ count as exposure or confounder variable fail to describe
how the time-point of change in CD4+ count was determined
[13,14,15,16,17,18,19,20,21,22].
The rate of change in CD4+ count is highest in the first months
after initiation of ART [9]. The dataset including all CD4+ counts
had a particularly high frequency of measurements in the first three
Table 3. Person-time, rates of tuberculosis and hazard ratios for tuberculosis using clinical cohort data and different methods to
estimate the time-point of change of CD4+ count.
CD4+ strata
(cells/uL) Date of measurement analysis Midpoint analysis Linear interpolation analysis
Survival and Cox regression analysis using all available CD4+ counts
Events PY Rate HR Events PY Rate HR Not performed*
#200 19 128.9 14.7 1 19 119.0 16.0 1
201–350 8 261.2 3.1 0.26 (0.11–0.61) 8 255.4 3.1 0.25 (0.11–0.55)
.350 11 378.7 2.9 0.34 (0.15–0.75) 11 394.5 2.8 0.29 (0.13–0.65)
Survival and Cox regression analysis using 6 monthly CD4+ counts only
Events PY Rate HR Events PY Rate HR Events PY Rate HR
#200 22 176.6 12.5 1 18 140.2 12.8 1 20 152.1 13.2 1
201–350 10 256.4 3.9 0.41 (0.19–0.88) 13 246.2 5.3 0.52 (0.25–1.08) 12 261.9 4.6 0.45 (0.22–0.95)
.350 6 335.7 1.8 0.25 (0.06–0.66) 7 382.3 1.8 0.24 (0.09–0.62) 6 354.7 1.7 0.22 (0.08–0.60)
Survival and Cox regression analysis using 6 monthly CD4+ counts and 15% randomly missing
Events PY Rate HR Events PY Rate HR Events PY Rate HR
#200 16.1 184.7 8.7 1 18.7 145.9 12.8 1 16.1 158.6 10.2 1
201–350 14.5 255.8 5.7 0.86 (0.42–1.77) 12.7 245.9 5.2 0.51 (0.24–1.05) 14.5 262.9 5.5 0.73 (0.35–1.510
.350 7.4 326.2 2.3 0.49 (0.19–1.25) 6.6 374.5 1.8 0.23 (0.09–0.59) 7.4 344.8 2.1 0.40 (0.15–1.02)
*Linear interpolation analysis was not performed for the analysis using all available CD4+ counts, as the result was not expected to differ greatly compared to the date
of measurement and midpoint analysis.
doi:10.1371/journal.pone.0027763.t003
Table 4. Estimated area under the CD4+ count curve using simulated data and different methods to estimate the time-point of
change of CD4+ count.
Baseline CD4+
count of the
cohort Time Cumulative area under the CD4+ count curve
True
Date of measurement
method 6 monthly
CD4+ counts
Date of measurement
method 3 monthly
CD4+ counts
Linear interpolation
method 6 monthly
CD4+ counts
Midpoint method 6
monthly CD4 counts
25–50 cells/uL 1 year 145 99 123 120 142
5 years 1348 1272 1311 1307 1342
51–100 cells/uL 1 year 180 138 160 157 177
5 years 1435 1368 1403 1399 1430
101–150 cells/uL 1 year 228 186 208 205 225
5 years 1662 1597 1631 1627 1657
151–200 cells/uL 1 year 282 238 261 258 278
5 years 1862 1801 1833 1829 1856
201–300 cells/uL 1 year 345 305 326 323 342
5 years 2180 2121 2152 2148 2274
Mixed 1 year 237 194 216 213 233
5 years 1704 1639 1673 1669 1699
doi:10.1371/journal.pone.0027763.t004
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time spent with low CD4+ counts was overestimated in all analyses
conducted on a dataset with only 6 monthly CD4+ counts compared
to analysis using a dataset with all available CD4+ counts. As a result
TB incidence rates were underestimated in the low CD4+ count
strata. The difference in person-time spent with low CD4+ counts
wassmallest in the midpoint analysis,but rates and hazardratios were
nevertheless strongly biased using the dataset with 6-monthly CD4+
counts. The bias was due to a smaller number of events estimated to
occur in the low CD4+ count strata, which was probably due to
chance and small sample size. The analysis using modeled CD4+
count data showed that the midpoint analysis estimated person-time
and rates most accurately. The linear interpolation method estimated
person-time and rates more accurately compared to the date of
measurement, but less so when compared to the midpoint methods.
However, more than one interpolation or possibly daily interpolation
is likely to improve the accuracy of these estimates.
Our study confirms and extends the findings of a study from
Co ˆte d’Ivoire [23]. In this study by Deuffic-Bruban et al., person-
time spent at low CD4+ counts (,50 cells/uL) was highest in the
date of measurement analysis and lowest in the analysis assuming
that the CD4+ count changed immediately to the level of the next
measurement [23]. Estimates of rates of opportunistic infections
were highest (249/100 PYs) in the analysis assuming an immediate
change, followed by the linear interpolation (210/100 PYs) and
date of measurement analysis (130/100 PYs). However this study
is not comparable to our study or to routine programmatic data
because of the very high frequency of CD4+ counts (median time
between the last CD4+ measurements 1–1.8 months) throughout
the study (compared to a median of 3 months in our study) which
means that the differences between methods will be less
pronounced. Deufic-Burban et al. did not compare the results
from the original dataset and datasets with less frequent
measurements and thus they were unable to assess the extent of
bias that would be seen in those situations. In contrast, we used the
dataset with frequent measurements as a gold standard and
compared it to a generated dataset with only 6-monthly
measurements (a dataset comparable to most clinical cohort data).
Another further important addition in our study was that we used
the midpoint method. This method gave a good approximation to
the time spent at low CD4+ count strata.
Most analyses investigating the effect of time-updated CD4+
counts on clinical outcomes use CD4+ count categories
[14,19,21,24,25]. Categorizing a continuous variable such as
CD4+ count increases the problem of misclassification since small
differences can result in a change in category. Bias introduced by
categorization needs to be taken into account when analyzing and
interpreting the results from time-updated CD4+ count analysis.
Limitations of the clinical cohort analysis are the small sample size,
the small number of events and the relatively high baseline CD4+
count. The effect estimates calculated in full analysis were
imprecise and the extent of bias due to different methods was
uncertain from the clinical cohort analysis alone. However the
analysis using modeled data confirmed that person-time at higher
CD4+ counts and rates were more profoundly underestimated
using the date of measurement method compared to the midpoint
method. Missing data was randomly missing in the newly created
datasets. This is unlikely to be the case in clinical cohorts, where
missingness could be more likely in healthy patients with fewer
scheduled visits or sicker patients due to difficulties in accessing
care. TB rates within CD4+ count strata were assumed constant in
the modeled dataset which might not accurately reflect the reality.
Thus estimated TB rates might be even more biased if true TB
rates differ according to CD4+ count within CD4+ count strata.
Analysis using time-updated CD4+ counts as exposure or
confounder should consider using the midpoint method as a simple
way to reduce bias. In addition authors should be encouraged to
clearly describe the assumption underlying the time-point of change
in CD4+ count and researchers conducting meta-analyses should
contact authors to determine the method used.
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